The proliferation of new drugs challenges clinicians to keep abreast of new developments and to integrate clinical expertise with the best available clinical evidence. Pressures of the introduction (and cost) of new drugs and technologies, an aging population and the increasing expectations of patients are forcing policy makers in developed countries to look at how they are to control the increasing cost of health care. The pharmaceutical industry is keen to recover the costs spent on research and development of new pharmaceuticals. Increasingly economic analyses are being used to justify policies and the use of resources, by introducing measures of cost and quality as well as effectiveness. Moreover decisions on what should and should not ...
Abstract: Countries struggling to fund new premium priced medicines with ever increasing prices. In ...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
The research question was to determine if it is possible to develop a systematic approach to the man...
The research question was to determine if it is possible to develop a systematic approach to the man...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Introduction: There is continued unmet medical need for new medicines across countries especially fo...
The cost of the development of a new pharmaceutical product from its conception and synthesis throug...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
One function of drug formularies is to allow health care providers to exert some control over spendi...
The pharmaceutical regulatory framework is a complex system requiring great diligence when requestin...
Abstract: Countries struggling to fund new premium priced medicines with ever increasing prices. In ...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
The research question was to determine if it is possible to develop a systematic approach to the man...
The research question was to determine if it is possible to develop a systematic approach to the man...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Introduction: There is continued unmet medical need for new medicines across countries especially fo...
The cost of the development of a new pharmaceutical product from its conception and synthesis throug...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Medicines have made an appreciable contribution to improving health. However, even high-income count...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
One function of drug formularies is to allow health care providers to exert some control over spendi...
The pharmaceutical regulatory framework is a complex system requiring great diligence when requestin...
Abstract: Countries struggling to fund new premium priced medicines with ever increasing prices. In ...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...
Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-c...